In utero exposure to the endocrine disruptor di-(2-ethylhexyl) phthalate promotes local adipose and systemic inflammation in adult male offspring

Nutrition and Diabetes

Volumn 4, Issue MAY, 2014, Pages

  Campioli, E ^a,b   Martinez Arguelles, D B ^a,b   Papadopoulos, V ^a,b  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C PEPTIDE; C REACTIVE PROTEIN; CD163 ANTIGEN; GLUCOSE; INSULIN; INTERLEUKIN 6; MESSENGER RNA; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; TUMOR NECROSIS FACTOR; ADIPOCYTOKINE; CYTOKINE; ENDOCRINE DISRUPTOR;

ADIPOSE TISSUE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL DIFFERENTIATION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EPIDIDYMIS FAT; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOFLUORESCENCE MICROSCOPY; INFLAMMATION; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; METABOLISM; NONHUMAN; PERINATAL PERIOD; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROADIPOCYTE; PROGENY; PROTEIN BLOOD LEVEL; RAT; RETROPERITONEAL FAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE HOMOGENATE; WHITE ADIPOSE TISSUE; ADIPOCYTE; BIRTH; DIFFERENTIATION; ENDOCRINE FUNCTION; GESTATIONAL AGE; HOMOGENATE; IMMUNOFLUORESCENCE; MACROPHAGE INFILTRATION; PRENATAL DRUG EXPOSURE; SPRAGUE DAWLEY RAT; UPREGULATION;

EID: 84902368639     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2014.13     Document Type: Article

References (62)

1. Halden RU. Plastics and health risks. Annu Rev Public Health 2010; 31: 179-194.
2. German Federal Environment Agency. [Substance monograph for phthalates - New and updated reference and oxidized monoester metabolites in urine of children-and adults. Opinion of the Commission 'Human-Biomonitoring' by the Federal Environment Agency]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2011; 54: 770-785.
3. Frederiksen H, Skakkebaek NE, Andersson AM. Metabolism of phthalates in humans. Mol Nutr Food Res 2007; 51: 899-911.
4. Calafat AM, Slakman AR, Silva MJ, Herbert AR, Needham LL. Automated solid phase extraction and quantitative analysis of human milk for 13 phthalate metabolites. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 805: 49-56.
5. Duty SM, Silva MJ, Barr DB, Brock JW, Ryan L, Chen Z et al. Phthalate exposure and human semen parameters. Epidemiology 2003; 14: 269-277.
6. Green R, Hauser R, Calafat AM, Weuve J, Schettler T, Ringer S et al. Use of di(2-ethylhexyl) phthalate-containing medical products and urinary levels of mono(2-ethylhexyl) phthalate in neonatal intensive care unit infants. Environ Health Perspect 2005; 113: 1222-1225.
7. Rock G, Labow RS, Tocchi M. Distribution of di(2-ethylhexyl) phthalate and products in blood and blood components. Environ Health Perspect 1986; 65: 309-316.
8. Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP et al. Urinary levels of seven phthalate metabolites in the U.S. population from the National Health and Nutrition Examination Survey (NHANES) 1999-2000. Environ Health Perspect 2004; 112: 331-338.
9. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421-424.
10. Martinez-Arguelles DB, Campioli E, Culty M, Zirkin BR, Papadopoulos V. Fetal origin of endocrine dysfunction in the adult: The phthalate model. J Steroid Biochem Mol Biol 2013; 137: 5-17.
11. Joensen UN, Frederiksen H, Jensen MB, Lauritsen MP, Olesen IA, Lassen TH et al. Phthalate excretion pattern and testicular function: a study of 881 healthy danish men. Environ Health Perspect 2012; 120: 1397-1403.
12. Sjoberg P, Bondesson U, Gray TJ, Ploen L. Effects of di-(2-ethylhexyl) phthalate and five of its metabolites on rat testis in vivo and in in vitro. Acta Pharmacol Toxicol (Copenh) 1986; 58: 225-233.
13. Culty M, Thuillier R, Li W, Wang Y, Martinez-Arguelles DB, Benjamin CG et al. In utero exposure to di-(2-ethylhexyl) phthalate exerts both short-term and longlasting suppressive effects on testosterone production in the rat. Biol Reprod 2008; 78: 1018-1028.
14. Mylchreest E, Cattley RC, Foster PM. Male reproductive tract malformations in rats following gestational and lactational exposure to Di(n-butyl) phthalate: an antiandrogenic mechanism? Toxicol Sci 1998; 43: 47-60.
15. Martinez-Arguelles DB, Culty M, Zirkin BR, Papadopoulos V. In utero exposure to di-(2-ethylhexyl) phthalate decreases mineralocorticoid receptor expression in the adult testis. Endocrinology 2009; 150: 5575-5585.
16. Martinez-Arguelles DB, Guichard T, Culty M, Zirkin BR, Papadopoulos V. In utero exposure to the antiandrogen di-(2-ethylhexyl) phthalate decreases adrenal aldosterone production in the adult rat. Biol Reprod 2011; 85: 51-61.
17. Amatruda JM, Harman SM, Pourmotabbed G, Lockwood DH. Depressed plasma testosterone and fractional binding of testosterone in obese males. J Clin Endocrinol Metab 1978; 47: 268-271.
18. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000; 106: 1553-1560.
19. Tirabassi G, Gioia A, Giovannini L, Boscaro M, Corona G, Carpi A et al. Testosterone and cardiovascular risk. Intern Emerg Med 2013; 8(Suppl 1): S65-S69.
20. Campioli E, Batarseh A, Li J, Papadopoulos V. The endocrine disruptor mono-(2-ethylhexyl) phthalate affects the differentiation of human liposarcoma cells (SW 872). PLoS One 2011; 6: e28750.
21. Feige JN, Gelman L, Rossi D, Zoete V, Metivier R, Tudor C et al. The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. J Biol Chem 2007; 282: 19152-19166.
22. Ellero-Simatos S, Claus SP, Benelli C, Forest C, Letourneur F, Cagnard N et al. Combined transcriptomic-(1)H NMR metabonomic study reveals that monoethylhexyl phthalate stimulates adipogenesis and glyceroneogenesis in human adipocytes. J Proteome Res 2011; 10: 5493-5502.
23. Hao C, Cheng X, Xia H, Ma X. The endocrine disruptor mono-(2-ethylhexyl) phthalate promotes adipocyte differentiation and induces obesity in mice. Biosci Rep 2012; 32: 619-629.
24. Hao C, Cheng X, Guo J, Xia H, Ma X. Perinatal exposure to diethyl-hexyl-phthalate induces obesity in mice. Front Biosci (Elite Ed) 2013; 5: 725-733.
25. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661.
26. Center for Drug Evaluation and Research (CDER). Pharmacology and Toxicology, Guidance for Industry. Estimating the Maximum Safe Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, 2005.
27. Pardina E, Ferrer R, Baena-Fustegueras JA, Rivero J, Lecube A, Fort JM et al. Only C-reactive protein, but not TNF-alpha or IL6, reflects the improvement in inflammation after bariatric surgery. Obes Surg 2012; 22: 131-139.
28. Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G et al. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond) 2007; 31: 1420-1428.
29. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
30. Hatch EE, Nelson JW, Stahlhut RW, Webster TF. Association of endocrine disruptors and obesity: perspectives from epidemiological studies. Int J Androl 2010; 33: 324-332.
31. Casals-Casas C, Feige JN, Desvergne B. Interference of pollutants with PPARs: endocrine disruption meets metabolism. Int J Obes (Lond) 2008; 32(Suppl 6): S53-S61.
32. Fowler PA, Bellingham M, Sinclair KD, Evans NP, Pocar P, Fischer B et al. Impact of endocrine-disrupting compounds (EDCs) on female reproductive health. Mol Cell Endocrinol 2012; 355: 231-239.
33. Schmidt JS, Schaedlich K, Fiandanese N, Pocar P, Fischer B. Effects of di(2-ethylhexyl) phthalate (DEHP) on female fertility and adipogenesis in C3H/N mice. Environ Health Perspect 2012; 120: 1123-1129.
34. Heindel JJ, vom Saal FS. Role of nutrition and environmental endocrine disrupting chemicals during the perinatal period on the aetiology of obesity. Mol Cell Endocrinol 2009; 304: 90-96.
35. Kobayashi K, Miyagawa M, Wang RS, Suda M, Sekiguchi S, Honma T. Effects of in utero and lactational exposure to di(2-ethylhexyl)phthalate on somatic and physical development in rat offspring. Ind Health 2006; 44: 652-660.
36. Hurst CH, Waxman DJ. Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. Toxicol Sci 2003; 74: 297-308.
37. Bolling AK, Ovrevik J, Samuelsen JT, Holme JA, Rakkestad KE, Mathisen GH et al. Mono-2-ethylhexylphthalate (MEHP) induces TNF-alpha release and macrophage differentiation through different signalling pathways in RAW264.7 cells. Toxicol Lett 2012; 209: 43-50.
38. Nishioka J, Iwahara C, Kawasaki M, Yoshizaki F, Nakayama H, Takamori K et al. Di-(2-ethylhexyl) phthalate induces production of inflammatory molecules in human macrophages. Inflamm Res 2012; 61: 69-78.
39. Rakkestad KE, Holme JA, Paulsen RE, Schwarze PE, Becher R. Mono(2-ethylhexyl) phthalate induces both pro- and anti-inflammatory responses in rat alveolar macrophages through crosstalk between p38, the lipoxygenase pathway and PPARalpha. Inhal Toxicol 2010; 22: 140-150.
40. Hansen JS, Larsen ST, Poulsen LK, Nielsen GD. Adjuvant effects of inhaled mono-2-ethylhexyl phthalate in BALB/cJ mice. Toxicology 2007; 232: 79-88.
41. Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem 2009; 48: 111-136.
42. Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 2004; 18: 1657-1669.
43. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
44. Calabrese EJ, Baldwin LA. Hormesis: the dose-response revolution. Annu Rev Pharmacol Toxicol 2003; 43: 175-197.
45. Fan J, Traore K, Li W, Amri H, Huang H, Wu C et al. Molecular mechanisms mediating the effect of mono-(2-ethylhexyl) phthalate on hormone-stimulated steroidogenesis in MA-10 mouse tumor Leydig cells. Endocrinology 2010; 151: 3348-3362.
46. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesityinduced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614.
47. Calabro P, Chang DW, Willerson JT, Yeh ET. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005; 46: 1112-1113.
48. Jabs WJ, Logering BA, Gerke P, Kreft B, Wolber EM, Klinger MH et al. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol 2003; 33: 152-161.
49. Imamura T, Tanaka S, Yoshida H, Kitamura K, Ikegami A, Takahashi A et al. Significance of measurement of high-sensitivity C-reactive protein in acute pancreatitis. J Gastroenterol 2002; 37: 935-938.
50. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005; 69: 29-35.
51. Martinez-Arguelles D, Campioli E, Lienhart C, Fan J, Culty M, Zirkin B et al. In utero exposure to the endocrine disruptor di-(2-ethylhexyl) phthalate induces longterm changes in gene expression in the adult male adrenal gland. Endocrinology 2014; 155: 1667-1678.
52. Falcao-Pires I, Castro-Chaves P, Miranda-Silva D, Lourenco AP, Leite-Moreira AF. Physiological, pathological and potential therapeutic roles of adipokines. Drug Discov Today 2012; 17: 880-889.
53. Segura J, Ruilope LM. Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr 2007; 10: 1151-1155.
54. Yvan-Charvet L, Massiera F, Lamande N, Ailhaud G, Teboul M, Moustaid-Moussa N et al. Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology 2009; 150: 1421-1428.
55. Harte A, McTernan P, Chetty R, Coppack S, Katz J, Smith S et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 2005; 111: 1954-1961.
56. Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001; 15: 2727-2729.
57. Martinez-Arguelles DB, McIntosh M, Rohlicek CV, Culty M, Zirkin BR, Papadopoulos V. Maternal in utero exposure to the endocrine disruptor di-(2-ethylhexyl) phthalate affects the blood pressure of adult male offspring. Toxicol Appl Pharmacol 2013; 266: 95-100.
58. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 2002; 20: 965-973.
59. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356-362.
60. Smathers RL, Petersen DR. The human fatty acid-binding protein family: evolutionary divergences and functions. Hum Genomics 2011; 5: 170-191.
61. Cao Z, Umek RM, McKnight SL. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev 1991; 5: 1538-1552.
62. Langin D, Frühbeck G, Frayn KN, Lafontan M. Adipose tissue: development, anatomy and functions. In: Williams G, Frühbeck G (eds) Obesity: Science to Practice. John Wiley & Sons, Ltd: Chichester, West Sussex, UK, 2009, pp 79-108.